Victory Capital Management
RKDA icon

Victory Capital Management’s Arcadia Biosciences RKDA Stock Holding History

Victory Capital Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-61
Closed -$6K – 3125
2020
Q1 		$6K Buy
+61
New +$10.6K ﹤0.01% 3440
2019
Q4 		– Sell
-21
Closed -$4K – 3147
2019
Q3 		$4K Buy
+21
New +$4.03K ﹤0.01% 3515

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Victory Capital Management's RKDA Position: Q2 2020 in Review

Victory Capital Management sold out of Arcadia Biosciences (RKDA) in Q2 2020, closing a stake of 61 shares — an estimated $6K sold.

Victory Capital Management first reported a position in RKDA in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 15 funds tracked by Wall St. Rank hold RKDA as of Q2 2020.

  • Victory Capital Management reported no remaining Arcadia Biosciences position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 61 Arcadia Biosciences shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Arcadia Biosciences in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Arcadia Biosciences position peaked at $6K in Q1 2020.
  • 15 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.